Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CTx-TFEB
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Novo Holdings
Deal Size : $33.0 million
Deal Type : Series A Financing
Coave Secures €32M Series A to Advance Genetic Medicine Pipeline
Details : The funding will also enable Coave to advance its lead preclinical assets toward clinical development of CTx-TFEB. It is being evaluated for treating Amyotrophic Lateral Sclerosis.
Product Name : CTx-TFEB
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 09, 2025
Lead Product(s) : CTx-TFEB
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Novo Holdings
Deal Size : $33.0 million
Deal Type : Series A Financing
Lead Product(s) : CTx-PDE6b
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
eyeDNA to Present Follow-up Data on Gene Therapy HORA-PDE6b for Retinitis at ARVO 2024
Details : Coave lead program HCTx-PDE6b (AAV2/5-hPDE6B), an AAV5-based gene replacement therapy, is being evaluated in a Phase I/II trial for the treatment of retinitis pigmentosa.
Product Name : CTx-PDE6b
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 25, 2024
Lead Product(s) : CTx-PDE6b
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CTx-TFEB
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : ALS Association
Deal Size : $2.9 million
Deal Type : Funding
Coave Therapeutics Receives Grant from Als Association for CTx-Tfeb Program
Details : The funding will support Coave in developing CTx-TFEB, which is being evaluated in preclinical studies for multiple system atrophy treatment.
Product Name : CTx-TFEB
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 29, 2024
Lead Product(s) : CTx-TFEB
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : ALS Association
Deal Size : $2.9 million
Deal Type : Funding
Lead Product(s) : CTx-PDE6b
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CTx-PDE6b is a clinical stage AAV5-based gene therapy for the treatment of retinitis pigmentosa (RP) caused by bi-allelic mutations of the PDE6b gene. There are currently no approved treatments for PDE6b RP.
Product Name : CTx-PDE6b
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 31, 2023
Lead Product(s) : CTx-PDE6b
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CTx-TFEB
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Institute of Neurodegenerative Diseases of Bordeaux
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will explore the development of gene therapy product CTx-TFEB, targeting the transcription factor EB (TFEB) for the treatment of alpha-synucleinopathies, such as Multiple System Atrophy (MSA) and idiopathic Parkinson’s disease (PD).
Product Name : CTx-TFEB
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 14, 2022
Lead Product(s) : CTx-TFEB
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Institute of Neurodegenerative Diseases of Bordeaux
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : CTx-GBA1
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : ABL Bio
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the two-stage collaboration both companies will initially combine their complementary expertise to co-develop manufacturing technologies for AAV-based gene therapy products including CTx-GBA1.
Product Name : CTx-GBA1
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 06, 2022
Lead Product(s) : CTx-GBA1
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : ABL Bio
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : CTx-PDE6b
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Laboratoires Thea
Deal Size : $87.3 million
Deal Type : Licensing Agreement
Details : Coave and Théa will co-develop CTx-PDE6b under the joint agreement. Coave retains rights to commercialize CTx-PDE6b in the US and Théa receives an exclusive license to commercialize CTx-PDE6b in Europe (EU27), Ukraine, Turkey, Russia and North Africa.
Product Name : CTx-PDE6b
Product Type : Cell and Gene therapy
Upfront Cash : $11.6 million
September 16, 2021
Lead Product(s) : CTx-PDE6b
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Laboratoires Thea
Deal Size : $87.3 million
Deal Type : Licensing Agreement
Lead Product(s) : CTx-PDE6b
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Seroba Life Sciences
Deal Size : $39.0 million
Deal Type : Series B Financing
Details : Coave Therapeutics will use the proceeds to support: its lead clinical program CTx-PDE6b; Developing its AAV Ligand Conjugate platform; Developing its AAV Ligand Conjugate (‘ALIGATER’) platform; Partnerships in key disease areas to progress novel coA...
Product Name : CTx-PDE6b
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 21, 2021
Lead Product(s) : CTx-PDE6b
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Seroba Life Sciences
Deal Size : $39.0 million
Deal Type : Series B Financing
Reset All
